Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00593112 · ClinicalTrials.gov registry record · Phase 4
Proton Magnetic Spectroscopy in Children and Adolescents With ADHD Before and After Treatment With OROS Methylphenidate
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 39
- Enrollment target
NCT00593112: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT00593112 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00593112, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 39 participants
- Enrollment target
Study Summary
This will be an open label study using daily does of up to 126mg/day of Concerta in the treatment of children and adolescents, ages 12-17, who meet DSM-IV criteria for ADHD. Specific hypotheses are as follows: Hypothesis 1: Children and adolescents with ADHD will have significantly higher ACC and DLPFC Glutamate/myo-Inositol containing compounds (Glu/Ino) and Glutamate/creatine + phosphocreatine (Glu/Cr) than matched HCS. Hypothesis 2: After six weeks of treatment, OROS methylphenidate will lower ACC and DLPFC Glu/Ino and Glu/Cr levels in children with ADHD who are methylphenidate responders.
Interventions
- OTHER No intervention
- DRUG OROS methylphenidate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00593112
The ClinicalTrials.gov registry entry for NCT00593112 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which No intervention is the first listed.
NCT00593112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00593112 about?
NCT00593112 is a clinical study titled "Proton Magnetic Spectroscopy in Children and Adolescents With ADHD Before and After Treatment With OROS Methylphenidate". This will be an open label study using daily does of up to 126mg/day of Concerta in the treatment of children and adolescents, ages 12-17, who meet DSM-IV criteria for ADHD. Specific hypotheses are as follows: Hypothesis 1: Children and adolescents with ADHD will have significantly higher ACC and D...
What is the current status of trial NCT00593112?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 39 participants. The study started on 2006-11. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00593112?
The interventions under investigation include: No intervention (OTHER), OROS methylphenidate (DRUG).
Who is sponsoring clinical trial NCT00593112?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.